Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions

Area of Science:

• Immunology
• Microbiology
• Gastroenterology

Background:

• Common variable immunodeficiency (CVID) is a primary antibody deficiency impacting IgG, IgA, and IgM levels.
• CVID frequently involves gastrointestinal and lung complications, with polygenic inheritance being common.
• The gut microbiota's role in CVID pathogenesis is under-explored.

Purpose of the Study:

• To investigate the gut microbiota profile in CVID patients.
• To explore the relationship between gut dysbiosis, systemic inflammation, and CVID-related conditions.
• To identify potential therapeutic targets within the gut microbiome.

Main Methods:

• Analysis of gut microbiota diversity (alpha and beta diversity) in CVID patients and controls.
• Measurement of plasma lipopolysaccharide (LPS) and immune activation markers (sCD14, sCD25).
• Assessment of IgA expression in duodenal tissue for CVID patients with enteropathy.

Main Results:

• CVID patients exhibit reduced gut microbial alpha and beta diversity compared to healthy controls.
• Elevated plasma LPS and markers of systemic immune activation (sCD14, sCD25) were observed in CVID patients.
• CVID patients with enteropathy showed decreased duodenal IgA expression.

Conclusions:

• Gut dysbiosis and systemic immune activation are associated with CVID.
• The precise molecular mechanisms linking gut microbiota to CVID complications like inflammation and tumorigenesis require further elucidation.
• The potential for microbiome-targeted therapies in CVID management remains an open question.